Keyphrases
Randomized Trial
100%
Once-daily
100%
Hereditary Angioedema
100%
Long-term Prophylaxis
100%
Open-label Extension
100%
Berotralstat
100%
Angioedema Attack
33%
Treatment-related Adverse Events
33%
Quality of Life Improvement
22%
Attack Rate
22%
Quality of Life
11%
Placebo
11%
Diarrhea
11%
Abdominal Pain
11%
Randomized Double-blind
11%
Placebo-controlled
11%
Multicenter Trial
11%
Drug Dependence
11%
Arthralgia
11%
Clinically Meaningful Improvement
11%
Urinary Tract Infection
11%
Long-term Safety
11%
Kallikrein Inhibitor
11%
Long-term Tolerability
11%
Control Evaluation
11%
Nasopharyngitis
11%
C1 Inhibitor Deficiency
11%
Medicine and Dentistry
Hereditary Angioedema
100%
Adverse Event
60%
Quality of Life
60%
Placebo
40%
Diarrhea
20%
Abdominal Pain
20%
Urinary Tract Infection
20%
Complement Component C1s Inhibitor
20%
Arthralgia
20%
Kallikrein Inhibitor
20%
Plasma Kallikrein
20%
Rhinopharyngitis
20%
Coronavirus Infection
20%
Pharmacology, Toxicology and Pharmaceutical Science
Angioneurotic Edema
100%
Adverse Event
60%
Placebo
40%
Tolerability
20%
Complement Component C1s Inhibitor
20%
Arthralgia
20%
Diarrhea
20%
Urinary Tract Infection
20%
Plasma Kallikrein
20%
Kallikrein Inhibitor
20%
Abdominal Pain
20%
Rhinopharyngitis
20%
Coronavirus Infection
20%